Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Oncotelic Therapeutics, Inc. (OTLC) had Return on Tangible Equity of -8.29% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-0.30M |
|
-- |
|
-- |
|
$0.10M |
|
$-0.10M |
|
$-0.26M |
|
$-0.36M |
|
$-0.36M |
|
$-0.36M |
|
$-0.36M |
|
$-0.36M |
|
$-0.36M |
|
$-0.10M |
|
$-0.06M |
|
407.42M |
|
407.42M |
|
$0.00 |
|
$0.00 |
|
| Balance Sheet Financials | |
$0.12M |
|
-- |
|
$26.54M |
|
$26.67M |
|
$19.48M |
|
-- |
|
-- |
|
$19.48M |
|
$7.18M |
|
$4.40M |
|
$7.18M |
|
408.29M |
|
| Cash Flow Statement Financials | |
$-0.17M |
|
-- |
|
$0.16M |
|
$0.11M |
|
$0.10M |
|
$-0.01M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.01 |
|
-- |
|
-- |
|
-- |
|
1.85 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.17M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-5.07% |
|
|
Return on Tangible Equity |
-8.29% |
-1.37% |
|
-5.07% |
|
$0.02 |
|
$-0.00 |
|
$-0.00 |
|